BioSpace3d
Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo
Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...
GlobalData on MSN3d
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...
Zacks.com on MSN7h
AstraZeneca Rises Almost 9% in a Month: How to Play the Stock
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
Hosted on MSN10d
IHH seeks up to $1.7b in compensation from JP’s Daiichi Sankyo over Fortis deal
Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer.
pharmaphorum3d
Ono poised to join Daiichi in TGCT market after FDA nod
Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...
The Edge Singapore13d
IHH’s unit seeks up to $1.7 bil in compensation from Japan’s Daiichi Sankyo over Fortis deal
IHH’s subsidiary Northern TK Venture (NTK) had filed a claim against Daiichi Sankyo saying the latter prevented NTK from ...
BioWorld1d
Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors
Becoming the second drug approved by the U.S. FDA for tenosynovial giant cell tumors, Deciphera Pharmaceuticals Inc.’s oral ...
No quick outcome from latest IHH-Daiichi lawsuit
The tussle between IHH Healthcare Bhd, Asia’s biggest private healthcare provider, and Daiichi Sankyo Co Ltd, a ...
Morningstar7d
Daiichi Sankyo Co Ltd 4568
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...